

TRANSGENOMIC PHARMACOGENOMIC SERVICES

Your Source for Pharmacogenomics, Biomarker and Mutation Discovery Research

Mutation Detection

Transgenomic has over 13 years experience as a leader in the field of DNA mutation screening.

Featuring:

- WAVE® Mutation Detection System
- SURVEYOR® Nuclease
- COLD-PCR

We also utilize the most advanced technology platforms available that drive accelerated drug discovery and biomarker development including:

- PCR/RT-PCR
- Capillary Electrophoresis
- Gene Sequencing
- Methylation Analysis
- FISH
- Chromosomal Micro Array
- IHC


By providing comprehensive mutation coverage, we can locate somatic and germline mutations including: novel variants, SNPs, CpG Island methylation status, mitochondrial mutations, mito-depletions, splice-donor sites, insertions and deletions.

Assay Design and Validation

We can provide assays designed specifically for your projects or choose from our list of gene targets. Our staff can advise you on how to customize your protocols to best meet your requirements and deliverables.

Pre-clinical to Clinical Trial Support

Upon request, we can perform any assay following GLP requirements or CLIA regulations — meeting the most stringent requirements or reporting guidelines.



Dilution analysis of low-level EGFR mutations in NSCLC (Non-small Cell Lung Cancer) patients are easily detected to <1% by TRANSGENOMIC's WAVE and SURVEYOR technologies but missed by sequencing (A). Only after WAVE/SURVEYOR fractionation, were mutations confirmed by sequencing (B). * Two fragments generated by SURVEYOR Nuclease digestion caused by a mutation and a \odot SNP occurrence identified in the second SURVEYOR cut in EGRF exon 21.¹

TRANSGENOMIC PHARMACOGENOMIC SERVICES

12325 Emmet Street

Omaha, NE 68164

Phone: (866) 500-GENE / (866) 500-4363

Fax: (402) 452-5447

E-mail: labservice@transgenomiclabs.com

www.pgx.transgenomic.com



TRANSGENOMIC®
the power of discovery